ABBV AbbVie InccompanySEC Filings & Insider Trading Activity 2026
Latest AbbVie Inc (ABBV) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 20, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for AbbVie Inc (ABBV) (SEC CIK 1551152), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
- • New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
Risk Factors
- • FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
- • Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
Management Discussion & Analysis
- • Revenue $61.2B, up 9% YoY on reported and constant currency basis
- • Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • Section 'risk_factors' was empty or not found.
Management Discussion & Analysis
- • Revenue $15.8B Q3 2025, up 9.1% vs $14.5B Q3 2024; Nine months $44.5B, up 8.0% vs $41.2B prior year
- • Gross margin approx. 66.4% Q3 2025 vs ~70.9% Q3 2024 (calc. from $10.47B/$15.78B vs $10.25B/$14.46B), decline due to $847M intangible impairments
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • Total debt issuance $8.0B across 7 tranches, maturities ranging 2028–2066, completed March 4, 2026
- • Floating rate tranche $750M due 2028; fixed rates range from 3.775% (2028) to 5.650% (2066)
Annual Reports Archive10-K
AI-powered analysis of AbbVie Inc (ABBV) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of AbbVie Inc (ABBV) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of AbbVie Inc (ABBV) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $58.1B | $54.3B | $56.3B | $61.2B |
| Gross Profit | $11.0B | $8.6B | $10.7B | $12.1B |
| Operating Income | — | $12.8B | $9.1B | $15.1B |
| Net Income | — | $4.9B | $4.3B | $4.2B |
| Gross Margin | 18.9% | 15.8% | 19.0% | 19.7% |
| Op. Margin | — | 23.5% | 16.2% | 24.6% |
| Net Margin | — | 9.0% | 7.6% | 6.9% |
| Balance Sheet | ||||
| Total Assets | — | $134.7B | $135.2B | $134.0B |
| Equity | — | $10.4B | $3.3B | -$3.3B |
| ROE | — | 46.9% | 128.7% | -129.2% |
Source: XBRL financial data from AbbVie Inc (ABBV) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 29, 2026 | — | — | — |
8-K | Apr 3, 2026 | — | — | — |
8-K | Mar 4, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 20, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 4, 2026 | — | — | |
8-K | Jan 7, 2026 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 4, 2025 | Jun 30, 2025 | — | |
10-Q | May 9, 2025 | Mar 31, 2025 | — | |
10-K | Feb 14, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 4, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 3, 2024 | Mar 31, 2024 | — | |
10-K | Feb 20, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 5, 2023 | Mar 31, 2023 | — | |
10-K | Feb 17, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 4, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Feb 18, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 2, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 2, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest ABBV SEC filings in 2026?
AbbVie Inc (ABBV) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ABBV file its most recent 10-K annual report?
AbbVie Inc (ABBV) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ABBV 10-Q quarterly reports?
AbbVie Inc (ABBV)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every ABBV 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ABBV filed recently?
AbbVie Inc (ABBV)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ABBV insider trading activity (Form 4)?
SignalX aggregates every ABBV Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ABBV file with the SEC?
AbbVie Inc (ABBV) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ABBV filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for AbbVie Inc (ABBV).
What is ABBV's SEC CIK number?
AbbVie Inc (ABBV)'s SEC CIK (Central Index Key) number is 1551152. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1551152 to look up all ABBV filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ABBV return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from AbbVie Inc (ABBV) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of AbbVie Inc SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 46+ filings.